230 related articles for article (PubMed ID: 33183562)
1. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
[TBL] [Abstract][Full Text] [Related]
2. The relationship between
Dolan RD; Maclay JD; Abbass T; Colville D; Buali F; MacLeod N; McSorley ST; Horgan PG; McMillan DC
Sci Rep; 2020 Nov; 10(1):20819. PubMed ID: 33257741
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: Implications for a clinically important framework in the assessment and treatment of advanced cancer.
Dolan RD; Daly L; Sim WMJ; Fallon M; Ryan A; McMillan DC; Laird BJ
Clin Nutr; 2020 Sep; 39(9):2889-2895. PubMed ID: 31926762
[TBL] [Abstract][Full Text] [Related]
4. The Relationship between ECOG-PS, mGPS, BMI/WL Grade and Body Composition and Physical Function in Patients with Advanced Cancer.
Dolan RD; Daly LE; Simmons CP; Ryan AM; Sim WM; Fallon M; Power DG; Wilcock A; Maddocks M; Bennett MI; Usborne C; Laird BJ; McMillan DC
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397102
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
6. Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer.
Rocha BMM; Dolan RD; Paiva CE; McGovern J; Paiva BSR; Preto DD; McMillan DC; Maia YCP; Laird BJ
J Pain Symptom Manage; 2023 Apr; 65(4):348-357. PubMed ID: 36493981
[TBL] [Abstract][Full Text] [Related]
7. An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer.
Dolan RD; Laird BJA; Klepstad P; Kaasa S; Horgan PG; Paulsen Ø; McMillan DC
Medicine (Baltimore); 2019 Sep; 98(37):e17019. PubMed ID: 31517821
[TBL] [Abstract][Full Text] [Related]
8. Are CT-Derived Muscle Measurements Prognostic, Independent of Systemic Inflammation, in Good Performance Status Patients with Advanced Cancer?
McGovern J; Dolan RD; Simmons C; Daly LE; Ryan AM; Power DG; Fallon MT; Laird BJ; McMillan DC
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444607
[TBL] [Abstract][Full Text] [Related]
9. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
[No Abstract] [Full Text] [Related]
10. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
[TBL] [Abstract][Full Text] [Related]
11. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer.
Dolan RD; Almasaudi AS; Dieu LB; Horgan PG; McSorley ST; McMillan DC
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):111-122. PubMed ID: 30460764
[TBL] [Abstract][Full Text] [Related]
12. The Relationship between Clinical Frailty Score, CT-Derived Body Composition, Systemic Inflammation, and Survival in Patients with Chronic Limb-Threatening Ischemia.
Bradley NA; Walter A; Roxburgh CSD; McMillan DC; Guthrie GJK
Ann Vasc Surg; 2024 Jul; 104():18-26. PubMed ID: 37356659
[TBL] [Abstract][Full Text] [Related]
13. The relationship between the modified frailty index score (mFI-5), malnutrition, body composition, systemic inflammation and short-term clinical outcomes in patients undergoing surgery for colorectal cancer.
McGovern J; Grayston A; Coates D; Leadbitter S; Hounat A; Horgan PG; Dolan RD; McMillan DC
BMC Geriatr; 2023 Jan; 23(1):9. PubMed ID: 36609242
[TBL] [Abstract][Full Text] [Related]
14. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.
Simmons CP; Koinis F; Fallon MT; Fearon KC; Bowden J; Solheim TS; Gronberg BH; McMillan DC; Gioulbasanis I; Laird BJ
Lung Cancer; 2015 Jun; 88(3):304-9. PubMed ID: 25870155
[TBL] [Abstract][Full Text] [Related]
15. Determinants of quality of life in patients with incurable cancer.
Daly LE; Dolan RD; Power DG; Ní Bhuachalla É; Sim W; Cushen SJ; Fallon M; Simmons C; McMillan DC; Laird BJ; Ryan AM
Cancer; 2020 Jun; 126(12):2872-2882. PubMed ID: 32267548
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system.
Laird BJ; Kaasa S; McMillan DC; Fallon MT; Hjermstad MJ; Fayers P; Klepstad P
Clin Cancer Res; 2013 Oct; 19(19):5456-64. PubMed ID: 23938289
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation.
Minami S; Ihara S; Kim SH; Yamamoto S; Komuta K
World J Oncol; 2018 Feb; 9(1):13-20. PubMed ID: 29581811
[TBL] [Abstract][Full Text] [Related]
18. Deep learning-based assessment of CT markers of sarcopenia and myosteatosis for outcome assessment in patients with advanced pancreatic cancer after high-intensity focused ultrasound treatment.
Nowak S; Kloth C; Theis M; Marinova M; Attenberger UI; Sprinkart AM; Luetkens JA
Eur Radiol; 2024 Jan; 34(1):279-286. PubMed ID: 37572195
[TBL] [Abstract][Full Text] [Related]
19. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.
Hacker UT; Hasenclever D; Baber R; Linder N; Busse H; Obermannova R; Zdrazilova-Dubska L; Valik D; Lordick F
Ann Oncol; 2022 Jul; 33(7):685-692. PubMed ID: 35395383
[TBL] [Abstract][Full Text] [Related]
20. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.
Higgins MI; Martini DJ; Patil DH; Nabavizadeh R; Steele S; Williams M; Joshi SS; Narayan VM; Sekhar A; Psutka SP; Ogan K; Bilen MA; Master VA
Cancer; 2021 Jun; 127(12):1974-1983. PubMed ID: 33760232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
